Introduction
============

It is widely accepted that prompt, appropriate antimicrobial chemotherapy is an important determinant of outcome in infected critically ill patients. The impact of treatment appropriateness on survival has been well documented during the course of ventilator-associated pneumonia,[@b1-tcrm-5-491]--[@b4-tcrm-5-491] bloodstream infections,[@b5-tcrm-5-491]--[@b7-tcrm-5-491] sepsis, severe sepsis, and septic shock.[@b8-tcrm-5-491]--[@b11-tcrm-5-491] Although the impact of treatment appropriateness has not been studied specifically in patients infected on admission to the intensive care unit (ICU), one might imagine that appropriate antimicrobial therapy is particularly warranted in this situation.

In all the above-mentioned studies,[@b1-tcrm-5-491]--[@b11-tcrm-5-491] appropriateness of antibiotic therapy was only judged according to microbiological documentation. Undocumented infections thus could not be evaluated. This represents an important limitation of the above-referenced studies, because 30% of hospital-acquired infections and 45% of community-acquired infections remain undocumented in ICUs.[@b12-tcrm-5-491] As our local anti-infective committee has established recommendations for empirical antibiotic therapy including clinically suspected microbiologically undocumented infections, we used them as a method of evaluating the appropriateness of empirical antibiotic prescriptions given for patients on admission to the ICU. Using this definition of treatment appropriateness, we characterized the quality of antibiotic treatment on admission, the factor(s) associated with treatment inappropriateness, and the impact of inappropriateness on in-hospital mortality attributed to the initial infection.

Materials and methods
=====================

Setting and patients
--------------------

This prospective study was carried out during a six-month period (February 12 to July 25, 2003) in the 14-bed medical ICU of Saint-Antoine Teaching Hospital in Paris, France. All patients receiving empirical curative antibiotic therapy in the first 24 hours following admission to the ICU were eligible. Empirical therapy was started after the collection of a minimum of two peripheral blood samples in 100% of cases, and of other clinically indicated microbiological samples in 88% of cases (bronchoalveolar lavage fluid, pleural fluid, urine, cerebrospinal fluid, pus, etc.).

Data collection
---------------

The following data were systematically recorded: date and time of admission, age, gender, prior hospitalization in the previous year, origin of the patient, ongoing antimicrobial chemotherapy on admission and eventual modification of that treatment, Simplified Acute Physiology Score (SAPS II), ventilatory support, vasopressor administration, indication(s) for antimicrobial chemotherapy, community-acquired or hospital-acquired infection (classified as hospital-acquired if diagnosed more than 48 hours after hospital admission), antibiotics prescribed, time between admission and administration of antibiotic therapy, and initiation of antibiotic therapy during the day time (between 8 AM and 8 PM) or at night. After 48 hours, we collected the microbiological data and recorded whether antimicrobial treatment was modified or not.

Justification and appropriateness of therapy
--------------------------------------------

One week after ICU admission, all the files were reevaluated by two investigators (JLB and JT). This provided a classification of antibiotic treatments: 1/justified (presence of infection) or not (no infection); 2/prescribed for a correctly identified source of infection or not (site of infection not found or misdiagnosed site of infection); 3/appropriate or not (appropriateness being defined as respect of the published local recommendations for empirical antibiotic treatment. This could be done only for clinically, biologically and/or radiologically established but microbiologically undocumented infections). Appropriateness was evaluated by the investigators (JLB, JT) and concerned both the molecules employed and their dosages. Our published local guidelines consist of an 80-page booklet updated every two years, which covers almost all infection sites. For example, concerning community-acquired broncho-pulmonary infections, the different presentations are defined (acute bronchitis, acute exacerbation of chronic obstructive pulmonary disease, acute pneumonia of the young adult \[not severe or severe\], acute pneumonia after aged 75 years \[not severe or severe or with comorbidities\] aspiration pneumonia) and, for each one, a first-line treatment is proposed (molecules and dosages) as well as some alternatives (two to four depending on the infection). This booklet is given personally to each clinician of our hospital. The recommendations present in this booklet are based on the practice guidelines of the Infectious Diseases Society of America and of the Société de Pathologie Infectieuse de Langue Française. Treatment was considered inappropriate when it did not respect these recommendations in terms of molecules and dosages, and when this resulted in a treatment inactive against the pathogens most frequently responsible for the type of infection presented by the patient.

Outcome
-------

We recorded in-hospital mortality related to the infection present on ICU admission. This assessment was done independently by the two main investigators; in the absence of consensus the chart was re-evaluated by the two investigators or by the entire medical staff of the ICU until a conclusion was drawn.

Statistical analysis
--------------------

The chi-squared test or Fisher's exact test was used to compare qualitative variables, and the Mann--Whitney test was used for quantitative variables. Logistic regression models were used to identify risk factors for in-hospital mortality caused by the the initial infection. Characteristics with p values below 0.20 in univariate analysis were included in multivariate models based on a backward elimination procedure. All statistical tests were two-sided, with a type I error of 5%.

Results
=======

During the study period, 374 patients were admitted to the ICU. One hundred twenty seven of them (34%) received curative antibiotic therapy within the first 24 hours. One hundred twenty two (96%) of these patients were treated for one focus of infection, and five patients for two foci (total 132 prescriptions). The baseline characteristics of the patients are shown in [Table 1](#t1-tcrm-5-491){ref-type="table"}. Patients who were given antibiotics on admission were older, had a higher SAPS II score, a longer ICU stay, and required a higher work load.

File review showed that 21 (16%) of the 132 prescriptions were unjustified because of absence of infection. The characteristics of the 111 justified curative antibiotic prescriptions, which concerned 107 patients (four patients were treated for two infections) are shown in [Table 2](#t2-tcrm-5-491){ref-type="table"}. Sixty-one (57%) of these 107 patients were outpatients, 39 (43%) were inpatients. 45 of these 107 patients (42%) had already received antibiotics on admission. This antibiotic therapy was frequently modified on admission (31/45, 69%), in most cases (81%) because it was considered inappropriate by the prescriber. Antibiotic therapy begun on admission was always reviewed 48 hours later and this led to treatment changes in 55% of the cases: narrowing (49%), escalation (6%). Most cases of treatment de-escalation were explained by the availability of microbiological data at 48 hours. Concerning treatment escalation, in most cases treatment was changed because on admission the nosocomial character of the infection had not been taken into account.

We first studied the appropriateness of the prescriptions according to our guidelines. Among the 111 justified prescriptions, 17 (15%) were microbiologically documented at admission and nine (8%) with either no identification of the source of infection (eight cases) or a misdiagnosed site of infection (one case: intra-abdominal infection misdiagnosed as pneumonia). For these 26 cases, our local empirical treatment guidelines were not useful for the prescriber and thus we did not include them in the evaluation.

We thus determined the adherence to the guidelines of 85 empirical antibiotic prescriptions for correctly diagnosed infections (77% of the 111 justified prescriptions): nine were classified as inappropriate (11%) and 76 appropriate (89%). All the nine inappropriate treatments were related to an inadequate choice of antimicrobial agent(s), but not to a wrong dosage. Univariate analysis ([Table 3](#t3-tcrm-5-491){ref-type="table"}) showed that treatment of a hospital-acquired infection was the sole factor significantly associated with nonadherence to our local guidelines.

Thirty-nine of these 85 prescriptions (46%) were secondarily documented following admission. Thus the total percentage of microbiologically documented infections at 48 hours was 50% (56/111, 17 on admission plus 39 secondarily).

Our last and main objective was to appreciate whether nonadherence to our local treatment guidelines was associated with in-hospital mortality due to the initial infection. Among the 26 in-hospital deaths (23% of the study population), the initial infection was considered to be the cause of death in 13 cases (50%). Four factors were significantly associated with mortality due to the initial infection: 1/usage of intravenous epinephrine or norepinephrine; 2/empirical treatment inappropriate or prescribed for an infection of unknown origin; 3/usage of certain classes of antibiotics (fluoroquinolones and hospital-used beta-lactams); 4/high SAPS II score ([Table 4](#t4-tcrm-5-491){ref-type="table"}). Mortality was much higher in case of inappropriate empirical treatment (44%, 4/9) and of empirical treatment without localization of the infection source (33%, 3/9) than in case of appropriate empirical treatment (5%, 4/73) and microbiologically documented treatment (12%, 2/16). There was a trend towards increased in-hospital mortality in case of modification of the antimicrobial chemotherapy given prior to admission, but this did not reach statistical significance (p = 0.13) ([Table 4](#t4-tcrm-5-491){ref-type="table"}).

Multiple logistic regression analysis showed that inappropriate treatment, fluoroquinolone usage, and a higher SAPS II score were independently associated with in-hospital mortality from the initial infection ([Table 4](#t4-tcrm-5-491){ref-type="table"}).

Discussion
==========

It is now widely accepted that early and appropriate antimicrobial therapy of infections has an impact on in hospital mortality in the ICU setting. To our knowledge there is no published study whose specific aim was to evaluate antimicrobial therapy prescribed on admission to the ICU and to determine the impact of its appropriateness on hospital mortality. The link between treatment inappropriateness and mortality has been clearly established for certain types of infections: ventilator-associated pneumonia, bloodstream infections, or infections complicated by severe sepsis or septic shock.[@b1-tcrm-5-491]--[@b12-tcrm-5-491] In the case of ventilator-associated pneumonia, it has even been shown that modifying an initial inappropriate therapy according to the microbiological documentation obtained by bronchoalveolar lavage does not translate in a better outcome.[@b3-tcrm-5-491] Thus it appears that the efficacy of initial therapy, and notably of initial therapy on admission to the ICU is crucial for clinical outcome and is more important than adaptation of the treatment to microbiological results.

In the present work, we first assessed the different aspects of antibiotic prescription in the 24 hours following admission in our ICU. We found that 34% of the patients received antimicrobial treatment within this time period. But in fact 29% of the patients admitted were really infected at admission which is nonetheless almost one third of the patients. This result is similar to that reported (21%) in the international multicenter study from Alberti and colleagues.[@b12-tcrm-5-491] This confirms that infection at admission to the ICU in an important issue. Another important point of our study is that 85% of the treatments were empirically prescribed, only 15% of the infections being microbiologically documented on admission. Similar results (14%) have been obtained in another study performed in one ICU.[@b13-tcrm-5-491] This stresses the importance of the appropriateness of initial empirical antibiotic therapy in the ICU setting.

To achieve that goal, one needs to be helped by local empirical treatment guidelines adapted to the susceptibility of the microorganisms and regularly reevaluated. In ventilator-associated pneumonia, it has been shown that the application of an empirical treatment guideline can increase the initial administration of appropriate antimicrobial treatment.[@b14-tcrm-5-491] In our hospital, local empirical prescription guidelines are available for almost all types of infections and we thus wanted to determine whether they were followed; if they were not, for which reasons; and if nonadherence to them had an impact on in-hospital mortality due to the initial infection.

Compared to the works that have already been performed and which were based on microbiological documentation, an advantage of our definition of treatment appropriateness is that it permits to evaluate the treatments of infections which remain undocumented, and this represented 50% of the cases in our study. This relatively high percentage could be explained by one main reason: 76% of the infections we investigated were community-acquired and Alberti and colleagues clearly showed that the documentation rates are lower for community-acquired infections compared to hospital-acquired or ICU-acquired infections.[@b12-tcrm-5-491] In their international prospective cohort study of 3034 infectious episodes, the documentation rates were 86%, 71%, and 55% for ICU-acquired, hospital-acquired, and community-acquired infections, respectively. Furthermore, the nonevaluation of undocumented infections could represent a bias, because infections due to microorganisms difficult to identify are therefore for the most part not taken into account in the evaluation. On the other hand, with our definition of treatment appropriateness infections microbiologically documented on admission could not be evaluated. But they represented only a small percentage of the cases included (15%). Furthermore, it is clear that the risk of inappropriate treatment is lower when microbiological documentation is available.

We found that 89% of the initial empirical prescriptions were appropriate. The percentages of appropriateness found by other workers are similar to ours (from 83% to 99%) in some studies[@b8-tcrm-5-491],[@b11-tcrm-5-491],[@b13-tcrm-5-491] and lower (70% to 77%) in others.[@b6-tcrm-5-491],[@b9-tcrm-5-491],[@b15-tcrm-5-491] However, our results are difficult to compare with those of other works because, in all these studies appropriateness was judged according to microbiological documentation.

We then wanted to assess which factors were associated with treatment inappropriateness and whether our definition of treatment inappropriateness based on treatment guidelines had an impact on in-hospital mortality due to the initial infection. By univariate analysis, the only factor associated with empirical inappropriate prescriptions was the hospital-acquired characteristics of the infection treated. Examination of the cases showed that the main cause for this association was that the hospital-acquired character of the infection was not taken into account in the initial prescription, and antibiotic-resistant hospital-acquired organisms were therefore not covered by the prescription.

Concerning the link with mortality due to the initial infection, we found by multivariate analysis that the risk of in-hospital mortality from the initial infection was more than 14 times higher in case of inappropriate empirical treatment. However, our work suffers from some limitations: first, it is a monocentric study; second the number of cases evaluated was relatively low leading to large confidence intervals; third, the way appropriateness was judged depended on our local prescription guidelines and cannot be generalized to other hospitals.

As regards to the types of infections included, the study performed by Kollef and colleagues[@b15-tcrm-5-491] is the only one that can be compared with our work. They performed a prospective cohort monocentric study to evaluate the relationship between inappropriate antimicrobial treatment of infections (all infections included) and hospital mortality. By multivariate analysis they also found that inappropriate antimicrobial treatment was the most important independent determinant of hospital mortality (adjusted OR 4.27, 95% CI: 3.35--5.44; p \< 0.001). However, two major differences exist between the two studies: First, Kollef and colleagues did not restrict their study to patients already infected on admission but also included ICU-acquired infections. Second, their definition of treatment inappropriateness was the classical one used in all studies so far performed: prescription of at least one antibiotic active against the microorganism(s) isolated.

The other independent risk factor for hospital mortality that we identified was prescription of fluoroquinolones. Nseir and colleagues showed that fluoroquinolone use was an independent risk factor for subsequent acquisition of multidrug resistant bacteria in the ICU by the patient.[@b16-tcrm-5-491] We did not observe this phenomenon among the seven patients who received fluoroquinolones and who died. But we observed that four of them were treated for hospital-acquired infections and in three of them treatment was inappropriate because the hospital-acquired character of the infection was not taken into account. Thus, fluoroquinolone-resistant organisms could have been implicated; but unfortunately these cases were not microbiologically documented. Concerning the three remaining patients treated with fluoroquinolones for community-acquired infections and then died, we found a link between the prescription and death for one patient: he presented with acute prostatitis and was treated empirically with cefotaxime and ofloxacin. This infection was secondarily microbiologically documented with a strain of *Enterocococcus faecalis* being isolated from blood and urine. It is well known that this species is resistant to both third-generation cephalosporins and fluoroquinolones. Fluoroquinolone prescription was not implicated in the death of the two other patients. They presented with bacteremia due to fluoroquinolone-susceptible *Staphylococcus aureus* and their death was attributable to the severity of the sepsis in both cases.

Our work also showed that infections of undetermined origin are not rare and carry a high mortality rate. This had already been observed in other studies which dealt with ICU patients suffering from severe infections: sepsis or septic shock.[@b8-tcrm-5-491],[@b17-tcrm-5-491] One likely explanation is that, when treating an occult infectious process, most physicians are reluctant to prescribe potent broad-spectrum agents immediately. This emphasizes the need for an aggressive search for a focus of infection in all infected patients admitted to the ICU.

This study is thus the first to show that nonadherence to local empirical antibiotic prescription guidelines for patients infected on ICU admission is independently associated with increased in-hospital mortality due to the initial infection. More studies are needed to confirm our findings.
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###### 

Baseline characteristics of the patients admitted to the ICU during the study period classified in two groups: study patients who were given curative antibiotic therapy on admission and all other patients

  Variable[a](#tfn1-tcrm-5-491){ref-type="table-fn"}                  Study patients (n = 127)   Other patients (n = 247)   p
  ------------------------------------------------------------------- -------------------------- -------------------------- ---------
  Age (years)                                                         60.8 ± 16.7                55.7 ± 19.0                \<0.01
  Male to female ratio                                                1.50                       1.44                       ns
  SAPS II                                                             41.9 ± 19.3                36.9 ± 22.4                \<0.01
  Length of ICU stay (days)                                           8.6 ± 13.3                 3.0 ± 4.3                  \<0.01
  Work load : Omega score[b](#tfn2-tcrm-5-491){ref-type="table-fn"}   126.8 ± 181                49.5 ± 71.2                \< 0.01
  ICU mortality                                                       12.5%                      11%                        ns

**Notes:**

Values are expressed as mean ± SD, except for male to female ratio and ICU mortality;

The Omega Score is composed of therapeutic items accorded 1 to 10 points, and is divided into three categories as follows: Category 1, items entered only at the time of their first application; Category 2, items entered at each application; and Category 3, items entered every day of application. The total score, which covers the entire length of stay, is calculated by adding the points obtained in the three categories.

**Abbreviation:** SAPS II, simplified acute physiology score.

###### 

Description of the justified curative antibiotic prescriptions administered on admission to the ICU (n = 111)

  Aspect                                                          Data                                                          
  --------------------------------------------------------------- ------------------------------------------------------------- ---------------
  Number of treatment indications per patient                     One for 103 patients, two for 4 patients: 111 prescriptions   
  Number of prescriptions for community-acquired infections       84 (76%)                                                      
  Number of prescriptions for nosocomial infections               27 (24%)                                                      
  Empirical treatment for correctly diagnosed infection           85 (77%)                                                      
  Empirical treatment for undiagnosed or misdiagnosed infection   9 (8%)                                                        
  Microbiologically documented treatment                          17 (15%)                                                      
  Number of monotherapies, bitherapies, and tritherapies          Monotherapies:                                                41 (37%)
                                                                  Bitherapies:                                                  65 (58.5%)
                                                                  Tritherapies:                                                 5 (4.5%)
  Classes of antibiotics prescribed, n = 180                      **Beta-lactams:**                                             **102 (57%)**
                                                                   Co-amoxiclav:                                                67
                                                                   Cefotaxime or ceftriaxone:                                   14
                                                                   Tazocillin:                                                  7
                                                                   Amoxicillin:                                                 8
                                                                   Ceftazidime:                                                 3
                                                                   Oxacillin:                                                   2
                                                                   Imipenem:                                                    1
                                                                  **Macrolides or pristinamycin:**                              **37 (20%)**
                                                                   Spiramycin:                                                  35
                                                                   Erythromycin:                                                1
                                                                   Pristinamycin:                                               1
                                                                  **Fluoroquinolones:**                                         **20 (11%)**
                                                                   Ofloxacin:                                                   14
                                                                   Ciprofloxacin:                                               6
                                                                  **Cotrimoxazole:**                                            **8 (4%)**
                                                                  **Aminoglycosides:**                                          **6 (3.5%)**
                                                                   Amikacin:                                                    5
                                                                   Gentamicin:                                                  1
                                                                  **Nitro-imidazoles:**                                         **3 (2%)**
                                                                  **Glycopeptides:**                                            **1 (0.5%)**
                                                                  **Other classes:**                                            **3 (2%)**
  Infection treated                                                Pneumonia:                                                   58 (52%)
                                                                   Bronchitis:                                                  21 (19%)
                                                                   Intra-abdominal:                                             6 (5.5%)
                                                                   Urinary tract:                                               6 (5.5%)
                                                                   Neuro-meningeal:                                             6 (5.5%)
                                                                   Various:                                                     7 (6.25%)
                                                                   Unknown origin:                                              7 (6.25%)

###### 

Univariate analysis of risk factors for inappropriate empirical antimicrobial therapy on admission (appreciated on 85 empirical prescriptions for correctly diagnosed infections; empirical prescriptions for misdiagnosed or undiagnosed infections (n=9) and microbiologically documented prescriptions (n = 17) were excluded)

  Factor                                             Inappropriate therapy (n = 9) No. (%)   Appropriate therapy (n = 76) No. (%)   p value
  -------------------------------------------------- --------------------------------------- -------------------------------------- --------------
  SAPS II score                                      45.8 ± 18.2                             39.0± 18.7                             0.22
  Sex (male)                                         8 (89)                                  45 (59)                                0.14
  Age                                                56 ± 12                                 58 ± 18                                0.99
  Mechanical ventilation                             6 (67)                                  38 (50)                                0.49
  Noninvasive ventilation                            2 (22)                                  10 (13)                                0.61
  Dopamine use                                       0 (0)                                   3 (4)                                  1.00
  Epinephrine or norepinephrine use                  3 (33)                                  9 (12)                                 0.11
  **Hospital-acquired infection**                    4 (44)                                  11 (14)                                **0.0475**\*
  Delay between admission and treatment (in hours)   3.67 ± 2.45                             4.30 ± 3.97                            0.98
  Treatment during the night                         4 (44)                                  25 (33)                                0.48
  Ongoing antimicrobial treatment on admission: no   6 (67)                                  51 (67)                                0.74
   Yes and unchanged                                 0 (0)                                   7 (9)                                  
   Yes and modified                                  3 (33)                                  18 (24)                                
  Use of tazocillin, ceftazidim or imipenem          2 (22)                                  4 (5)                                  0.12
  Other betalactam usage                             7 (78)                                  67 (88)                                0.33
  Aminoglycoside usage                               0 (0)                                   2 (3)                                  1.00
  Fluoroquinolone usage                              2 (22)                                  7 (9)                                  0.24
  Macrolide or pristinamycin usage                   6 (67)                                  29 (38)                                0.15
  Use of other antibiotics                           2 (22)                                  8 (11)                                 0.29
  Prior hospitalization in the preceding year        6 (67)                                  32 (43)                                0.29
  Patients receiving antibiotics before admission    2 (22)                                  34 (45)                                0.29
  Pneumonia or pleural fluid infection               7 (78)                                  44 (58)                                0.30
  Urinary tract infection                            1 (11)                                  1 (1)                                  0.20
  Other infection                                    1 (11)                                  31 (41)                                0.14

###### 

**A**Univariate analysis of risk factors for in-hospital mortality due to the initial infection (107 patients). **B**) Risk factors independently associated with in-hospital mortality due to to the initial infection

  Factor                                                              In-hospital mortality from the initial infection                 
  ------------------------------------------------------------------- -------------------------------------------------- ------------- ----------------
  **SAPS II score (mean ± SD)**                                       58.7 ± 25.5                                        38.9 ± 18.0   **0.005**\*
  Sex (male)                                                          10 (77)                                            57 (61)       0.36
  Age                                                                 66 ± 14                                            59 ± 17       0.14
  Mechanical ventilation                                              8 (62)                                             46 (49)       0.56
  Noninvasive ventilation                                             2 (15)                                             8 (9)         0.35
  Dopamine use                                                        1 (8)                                              5 (5)         0.55
  Epinephrine or norepinephrine use                                   8 (62)                                             10 (11)       **\< 0.001**\*
  Hospital-acquired infection                                         6 (46)                                             19 (20)       0.07
  Delay (hours) between admission and treatment (mean ± SD)           4.5 ± 2.6                                          4.5 ± 4.2     0.40
  Treatment during the night                                          6 (46)                                             32 (30)       0.35
  Ongoing antimicrobial treatment on admission: no                    5 (38)                                             61 (65)       0.13
   Yes and unchanged                                                  2 (15)                                             8 (9)         
   Yes and modified                                                   6 (46)                                             25 (27)       
  Use of tazocillin, ceftazidim or imipenem                           4 (31)                                             6 (6)         **0.02**\*
  Use of other beta-lactams                                           10 (77)                                            80 (85)       0.43
  Use of aminoglycosides                                              2 (15)                                             4 (4)         0.15
  Use of fluoroquinolones                                             7 (54)                                             12 (13)       **0.002**\*
  Use of macrolides or pristinamycin                                  3 (23)                                             35 (37)       0.37
  Use of other antibiotics                                            0 (0)                                              14 (15)       0.21
  Prior hospitalization in the preceding year                         8 (62)                                             43 (46)       0.38
  Pneumonia of pleural fluid infection                                5 (38)                                             55 (59)       0.16
  Urinary tract infection                                             2 (15)                                             4 (4)         0.15
  Other infection                                                     4 (31)                                             34 (36)       0.77
  Bacteremia                                                          3 (23)                                             8 (9)         0.13
  Microbiological documentation at 48 hours                           7 (54)                                             40 (43)       0.42
   Origin of the patient: emergency unit                              3 (23)                                             45 (48)       0.17
   Other unit of the hospital                                         8 (62)                                             33 (35)       
   Community                                                          2 (15)                                             16 (17)       
  Appropriate or excessive empirical treatment                        4 (31)                                             69 (73)       **0.002**\*
   Inappropriate empirical treatment                                  4 (31)                                             5 (5)         
   Empirical treatment without localization of the infection source   3 (23)                                             6 (6)         
   Microbiologically documented treatment                             2 (15)                                             14 (15)       
  **B)**                                                                                                                               
  **Risk factor**                                                     **OR (95% CI)**                                    **p value**   
                                                                                                                                       
  Inappropriate treatment                                             14.64 (2.17--98.97)                                0.006         
  Use of fluoroquinolones                                             8.22 (1.88--35.95)                                 0.005         
  Increasing SAPS II score (one-point increments)                     1.04 (1.01--1.07)                                  0.02          

**Abbreviations:** CI, confidence interval; OR, odds ratio; SAPS II, simplified acute physiology score; SD, standard deviation.
